Nektar Therapeutics (NKTR) Change in Cash (2010 - 2026)

Nektar Therapeutics' Change in Cash history runs 17 years deep, the most recent figure standing at $134.5 million for Q1 2026.

• On a quarterly basis, Change in Cash rose 2609.56% year-over-year to $134.5 million in Q1 2026; TTM through Mar 2026 was $110.7 million, a 1235.45% increase from a year earlier, with the FY2025 full-year figure at -$29.1 million, down 424.64% from the prior year.
• Change in Cash climbed to $134.5 million in Q1 2026 per NKTR's latest filing, from -$25.9 million in the prior quarter.
• Across five years, Change in Cash topped out at $134.5 million in Q1 2026 and bottomed at -$29.6 million in Q4 2023.
• The 5-year median for Change in Cash is $2.2 million (2024), against an average of $7.3 million.
• Across the five-year window, Change in Cash tumbled 374.57% in 2023 and jumped 2609.56% in 2026, its largest moves.
• Year by year, Change in Cash stood at -$17.5 million in 2022, then slumped by 69.09% to -$29.6 million in 2023, then jumped by 147.71% to $14.1 million in 2024, then sank by 283.24% to -$25.9 million in 2025, then surged by 618.84% to $134.5 million in 2026.
• Per Business Quant, the three latest NKTR Change in Cash figures stand at $134.5 million (Q1 2026), -$25.9 million (Q4 2025), and -$2.0 million (Q3 2025).